Last reviewed · How we verify

Placebo granule

Xiyuan Hospital of China Academy of Chinese Medical Sciences · Phase 3 active Small molecule ✓ Verified Jun 2026

Placebo granule is a Small molecule drug developed by Xiyuan Hospital of China Academy of Chinese Medical Sciences. It is currently in Phase 3 development. Also known as: Radiotherapy.

This drug is a placebo, meaning it has no active therapeutic effect.

Placebo granules are a type of intervention used in clinical studies, including those for Inflammatory Bowel Disease, Stroke, Critically Ill, IgA Nephropathy at High Risk of Developing ESRD, and Covid19. Placebo granules are a small molecule modality, classified as a type of intervention in clinical trials, but their exact mechanism of action is not specified in the provided information.

Likelihood of approval
58.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic namePlacebo granule
Also known asRadiotherapy
SponsorXiyuan Hospital of China Academy of Chinese Medical Sciences
ModalitySmall molecule
PhasePhase 3

Mechanism of action

As a placebo, it does not interact with any biological molecules or systems, and its effects are purely psychological or due to the natural course of the disease.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo granule

What is Placebo granule?

Placebo granule is a Small molecule drug developed by Xiyuan Hospital of China Academy of Chinese Medical Sciences.

How does Placebo granule work?

This drug is a placebo, meaning it has no active therapeutic effect.

Who makes Placebo granule?

Placebo granule is developed by Xiyuan Hospital of China Academy of Chinese Medical Sciences (see full Xiyuan Hospital of China Academy of Chinese Medical Sciences pipeline at /company/xiyuan-hospital-of-china-academy-of-chinese-medical-sciences).

Is Placebo granule also known as anything else?

Placebo granule is also known as Radiotherapy.

What development phase is Placebo granule in?

Placebo granule is in Phase 3.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing